December 4-6, 2020 Salt Lake City, UT + Live Stream |
For years Part III attendees have lamented, “So is that all there is? Can’t there be more? Although there are new articles, research, updates, literature critiques, and sarcasm (of course), the majority of this course will be problem solving, case management, mistakes to avoid, and tricks of the trade. The audience will consist of those with significant experience, questions, and issues which makes for an excellent experience for both me and participants, as we all learn from patients and ourselves. Extensive literature review in Parts I, II, & III have not allowed me to present all the interesting and complicated cases and situations that I have encountered in the last 15 years of practice. So bring your tough cases, comments, thoughts, and ideas and have another fun weekend with your talented peers. This will be a collection of the most talented and experienced physicians in this industry. Enjoy.
Prerequisites: Part I, II and III
One would think that 3 courses on HRT would be all that is needed to adequately practice BHRT. However attendees have requested that they want more, but with more complexity and problem solving as opposed to didactic. Hence Part IV.
Although there are new articles, research, updates, literature critiques, and sarcasm (of course), the majority of this course will be problem solving, case management, mistakes to avoid, and tricks of the trade. The audience will consist of those with significant experience, questions, and issues that make for an excellent experience for both me and participants as we all learn from patients and ourselves. Extensive literature review in Parts I, II, & III have not allowed me to present all the interesting and complicated cases and situations that I have encountered in the last 15 years of practice. I have included 60 of my most complex and problematic cases from the last 15 years but it will require you to have masterful understanding of Parts I, II, and III in order to understand the reasoning behind the treatment and management of these problematic cases.
First we will review the latest NAMS recommendations. It is a step in the right direction. However I will use the medical literature to, of course, prove to them what they should have said and done as opposed to their sole reliance on the WHI trial. It should be the summation of all available data that should dictate our treatment, not just one study. We will then review the evolution from testosterone causes prostate cancer to maybe it protects against cancer to now where we prescribe it to men with active cancer. Although commonly (incorrectly) thought to cause prostate cancer, estrogen has been a mainstay to treat and protect against prostate cancer. In fact it may be through aromatization that testosterone can protect against prostate cancer. We will also review at what level of estradiol results in a flip of the lipids that then become cardio-protective. Although it has been customary and fashionable to utilize aromatase inhibitors to block aromatization of testosterone to estrogen, the most recent study demonstrates using an AI increases gynecomastia, visceral and subq fat, cholesterol, and sexual dysfunction.
Please read the agenda and course outline for a more complete synopsis of topics and objectives. So bring your tough cases, comments, thoughts and ideas and have another fun weekend with your talented peers. This will be a collection of the most talented and experienced physicians in this industry. Caution: Part IV will be thought provoking, intense, and very complex. And just maybe you’ll be able to pass that Certification Exam.
Part IV: Complexities of Hormone Replacement Therapy: An Evidence Based Protocol Review - June 2020
This course has been approved for 21 AMA PRA Category 1 Credits, 21 Nursing Contact Hours (21 pharmacologic hours), 21 Hours Pharmacy Credit (knowledge based).
Workshop Schedule
Syllabus Information
All participants will receive an electronic syllabus with their registration. A printed syllabus is available for an additional cost of $40.00. The eSyllabus will be available for download at least one week prior to the course. An email notification will be sent when it is available for download and will include links and instructions. This early release provides an opportunity to download and review the materials prior to the course.
PLEASE NOTE: We request you download the material prior to the event as internet access in the meeting room may be limited. We will also have flash drives available for those that find this easier than downloading. The syllabus can be saved in Adobe Reader which allows participants to add "sticky notes" directly on the slide as the speaker is talking. These notes can be saved permanently to your document. Other recommended applications include iBooks (for apple mobile devices) and iAnnotate (for mobile devices). Lastly, put perhaps most important for many of us, a printed syllabus is available with an option for good old fashioned note taking.
Upon completion of this workshop, the health care professional will be able to:
1) Review prognosis and complications for radical prostatectomy, proton gun radiation therapy, brachytherapy, cryotherapy, HIFU, laser ablation, as well as costs.
2) Review management strategies and importance of testosterone utilization in prostate cancer survivors as well as literature support.
3) Evaluate the association of testosterone and estradiol levels and the risk of developing prostate cancer. Should we raise, block, or administer estrogen based on the literature?
4) Recognize that optimal thyroid levels are best as recent studies determine that high TSH levels are associated with increased arterial stiffness and plaque thereby increasing CVD risk.
5) Review the recent NAMS position statements that further distinguish the emerging differences in the therapeutic benefit-risk ratio between ERT & HRT at various ages and time intervals from onset of menopause.
6) Recognize high testosterone levels in women are associated with an increased risk of breast cancer. Also understand that studies show testosterone administration is protective against breast cancer and is apoptotic to cancer cells. This demonstrates that association does not prove causation and one should not extrapolate them to be the same.
7) Recognize high estrogen levels in men are associated with increased cardiovascular risk. However estrogen administration in men protects against heart disease and prostate cancer. This demonstrates another example where association does not imply causation.
8) Evaluate and discuss my 50 most difficult management cases involving HRT.
9) Identify current approaches to manage vaginal bleeding, DUB, and endometrial hyperplasia.
10) Discuss the recent medical evidence that seems to counter everything that you have learned in regards to preventing prostate cancer.
11) Review medical studies demonstrating the various mechanisms of estrogen’s ability to stop prostate cancer growth.
12) Identify how Traumatic Brain Injury affects quality of life by pituitary dysfunction: When and how to test and not miss it.
13) Evaluate recent literature demonstrating the mechanism by which synthetic progestins increase breast cancer development through the production of the RANKL protein.
14) Utilize dual intravaginal therapy to maximize the effect on atrophic vaginitis, chronic UTI, incontinence, and sexual dysfunction.
15) Review the historical perspective that pieces together the studies to understand the complexities in the NAMS recommendation for HRT.
16) Evaluate abnormal lab tests and various symptoms in complex and confusing cases.
17) Evaluate when to use estrogen in premenopausal women and when not to use it: Anovulation vs. amenorrhea.
18) Identify different types of estrogen and progesterone and when to prescribe each.
19) Review various scenarios that dictate when to switch to alternate forms of HRT, based on history, BMI, risks, and compliance.
20) Discuss Hair loss in women: Current approach to reverse hair loss.
21) Describe various alternatives in testosterone administration in women.
22) Review when to switch from oral to transdermal estrogen; when to switch from transdermal to oral estrogen.
23) Discuss the current approach to preventing CVD in women with Syndrome W (X).
24) Discuss how to treat the vagina with pills, patches, rings, and things.
25) Review of management strategies for progesterone intolerance.
26) Discuss HRT review, myths, updates, alternatives when the usual routine doesn’t work.
27) Update on diagnosis, treatment, and prevention of prostate cancer. Should we be prescribing estrogen to men instead of blocking it?
28) Review management strategies for estrogen intolerance.
29) Evaluate the best prevention and treatment for incontinence and UTI, from wet to dry and dry to wet. Prevention is the key before use of drugs or surgery.
30) Identify current recommendations from NAMS for HRT and ERT and how they differ from past recommendations.
31) Review the history as to why the world believes testosterone causes prostate cancer.
32) Review further data demonstrating that E2 is the best estrogen but not the safest.
33) Review literature of spironolactone and its BBW.
34) Discuss the most recent FDA BBW for testosterone as it pertains to MI, CVA, and DVT.
42) Review dosing and administration of tranexamic acid to stop your patients from bleeding.
Back to topFriday, December 4, 2020
7:30 AM - 8:00 AM |
Registration |
8:00 AM - 9:00 AM |
Section 1 - 30 Cases with Q and A
Speaker: Dr. Neal Rouzier |
9:00 AM - 10:00 AM |
Section A • Appreciate a literature review of which type of estrogen to use in which circumstances and why. Oral vs transdermal, risks vs. benefits, and recent NIH studies. • Evaluate the most important literature summary chapter on estrogen and progesterone that you will ever read proving the harm of estrogen deprivation and the benefit of replacement = a must for everyone’s library. • Review all the long-term studies demonstrating the effect of estrogen on morbidity and mortality and the pathophysiology behind it all. • Determine how to assess studies of association that do not prove causation in contrast to RCT’s that prove causation through interventional study. • Do not extrapolate to prove a theory as one must intervene to prove causality. Speaker: Dr. Neal Rouzier |
10:00 AM - 10:15 AM |
BREAK |
10:15 AM - 11:15 AM |
Section 2 - 30 Cases with Q and A
Speaker: Dr. Neal Rouzier |
11:15 AM - 12:15 PM |
Section B • Review the extensive literature on the beneficial effect of estrogen in men in the treatment and prevention of prostate cancer and heart disease = proves benefit= causation. • Understand the various methods for raising estrogen in men and consequences of each. • Evaluating the literature and understanding the difference between cause and effect and how it pertains to hormones. • Discuss how association does not prove causation and to prove this requires the need for RCT’s to differentiate. • Practice HRT according to the EBM and not confabulation = don’t lower estrogen. • Learn how to increase visceral fat, decrease libido, increase lipids, and increase dementia through aromatase inhibitors as per NEJM. Speaker: Dr. Neal Rouzier |
12:15 PM - 1:15 PM |
LUNCH |
1:15 PM - 2:15 PM |
Section 3 - 30 Cases with Q and A
Speaker: Dr. Neal Rouzier |
2:15 PM - 3:15 PM |
Section C • What level of testosterone is safest to maintain for prostate cancer protection? • Is it possible or safe to utilize testosterone in prostate cancer survivors and at what point in time? • Using testosterone in men with active cancer? What does the literature support and under what circumstances. • Understand the complexity of the saturation model that is demonstrated in the world’s literature. • Does testosterone cause prostate cancer or does it not? Well it depends. Yes it does but treatment does not, rather endogenous does but exogenous does not. • Review of the meta-analysis and world’s expert opinions. Speaker: Dr. Neal Rouzier |
3:15 PM - 3:30 PM |
BREAK |
3:30 PM - 4:30 PM |
Section 4 - 30 Cases with Q and A Treatment for high TSH and high Free T3. Really, what is estrogen dominance and is it really IR in disguise? • Hair loss in men vs. hair loss in women. • Blood donation with use of HGH, testosterone, finasteride. • When to use estrogen in premenopausal women and when not to. • When to measure it and when not to. Speaker: Dr. Neal Rouzier |
4:30 PM - 5:30 PM |
Section D Review the new NAMS recommendations for HRT with comparison of past recommendations- understanding why the change in attitude. • Evaluate whether they utilize all current literature on which to base their recommendations or are they still stuck on the WHI? My critique and commentary follows. • Discuss the pathophysiology of estrogen deprivation and biology of estrogen replacement. • Describe the nonsensical use of long-term of estrogen blockade in women. Speaker: Dr. Neal Rouzier |
5:30 PM - 6:30 PM |
Section 5 - 30 Cases with Q and A 40 case scenarios requiring alternate types of hormones. • Which vaginal estrogen to use, when, and why. • TOC for vaginal atrophy and UTI. Work-up and treatment for vaginal bleeding. Alternative treatment for excessive, non-pathological vaginal bleeding (DUB). • Vaginal estrogen troche, pills, patches, rings and things to protect the vagina. Speaker: Dr. Neal Rouzier |
Saturday December 5, 2020
7:30 AM - 8:00 AM | Registration |
8:00 AM - 9:00 AM | Section E and Section F Look at the advanced treatment of the vagina and how to make it work better with estrogen, DHEA, and Oxytocin.
Section F Review the diagnosis and treatment of prostate cancer-state of the art with MRI-S and laser ablation.
Speaker: Dr. Neal Rouzier |
9:00 AM - 10:00 AM | Section 6
Speaker: Dr. Neal Rouzier |
10:00 AM - 10:15 AM | BREAK |
10:15 AM - 11:15 AM | Section G
Speaker: Dr. Neal Rouzier |
11:15 AM - 12:15 PM | Section 7 - 30 Cases with Q and A Optimal levels of estrogen and progesterone in men.
Speaker: Dr. Neal Rouzier |
12:15 PM - 1:15 PM | LUNCH |
1:15 PM - 2:15 PM | Section H
Speaker: Dr. Neal Rouzier |
2:15 PM - 3:15 PM | Section I
Speaker: Dr. Neal Rouzier |
3:15 PM - 3:30 PM | BREAK |
3:30 PM - 5:30 PM | Section J
Speaker: Dr. Neal Rouzier |
5:30 PM - 6:15 PM | Section K Final review of the testosterone studies demonstrating testosterone causes an increase in MI. Letters to patients and doctors.
|
Sunday, December 6, 2020
7:30 AM - 8:00 AM | Registration |
8:00 AM - 9:00 AM | Section L .
Speaker: Dr. Neal Rouzier |
9:00 AM - 9:15 AM | BREAK |
9:15 AM - 11:00 AM | Section 8 50 complex cases, treatment and management Speaker: Dr. Neal Rouzier |
11:00 AM - 12:00 PM | Section M Questions and answers with case reviews from articles from Part IV:
|
12:15 PM - 12:15 PM | ADJOURN |
Neal Rouzier
Dr. Neal Rouzier is a pioneer in the bio identical hormone replacement field, practicing almost since its inception in the early 1990’s. He has dedicated his life’s work to uncovering the medical literature that supports safe and effective protocols for unique and personalized patient care. He is the Director of the Preventive Medicine Clinics of the Desert, specializing in the medical management of aging and preventive care for men and women. He has treated more than 2,000 patients with natural hormone replacement therapy and is recognized as a renowned leader and expert in the field. Additionally, Dr. Rouzier is the author of Natural Hormone Replacement for Men and Women: How to Achieve Healthy Aging. He has over 16 years of experience as an educator and practicing physician, and 29 years of Emergency Medicine experience at Queen of the Valley Hospital in West Covina, CA.
EARLY BIRD PRICE VALID NOW THRU: November 6, 2020 |
REGULAR PRICE EFFECTIVE: November 7, 2020 |
|
Medical Providers and Pharmacists |
$1,195.00 |
$1,295.00 |
Staff Member & Returning Attendees |
$675.00 |
$675.00 |
|
*Cancellation Policy
Cancellation and/or course change requests received more than 3 weeks in advance of the event will receive a full credit (less a $50.00 change fee) which will be applied to your account as a credit for use towards a future event/service. Any cancellations and/or changes received less than 3 weeks before the event, will incur a $350.00 processing fee and the remaining balance will be credited to your account.
Cancellations received less than 3 days prior to the start of the event are non-refundable. No shows are also non-refundable.
ACCREDITATION STATEMENTS
AMA PRA Category 1 Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Foundation for Care Management (FCM) and Worldlink Medical. The Foundation for Care Management is accredited by the ACCME to provide continuing medical education for physicians.
FCM designates this educational activity for a maximum of 20 AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with the extent of their participation in this activity.The ACCME defines a “Commercial Interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Nursing Statement
The Foundation for Care Management is an approved provider of continuing nursing education by the Western Multi-State Division (WMSD), Approver of Continuing Nursing Education an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. 20 Nursing contact hour(s).
Pharmacy Statement
The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program 0347-9999-20-004-L01-P Objectives appropriate for pharmacists. This activity is 20 Contact Hours Pharmacy Credit. *This CME is Knowledge Based (K). Initial release May 4, 2018.